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Abstract Natalizumab, a highly effective therapy for
relapsing-remitting multiple sclerosis, is associated with a risk
of progressive multifocal leukoencephalopathy (PML). The
objective of this analysis was to examine factors predicting
survival in a large natalizumab-associated PML global popu-
lation. Patients with natalizumab-associated PML identified
through postmarketing surveillance were followed up for up
to 24 months using a structured questionnaire completed by
treating physicians. Demographic and clinical characteristics,
JC viral load, magnetic resonance imaging (MRI) results, and
Expanded Disability Status Scale (EDSS) and Karnofsky Per-
formance Scale (KPS) scores were compared in survivors and
nonsurvivors. Kaplan-Meier analysis was used to model sur-
vival function. Among the 336 patients included in this anal-
ysis, 76 % survived, with mean follow-up time from PML
diagnosis of 16.1 months for survivors; mean time from diag-
nosis to death was 4.7 months for nonsurvivors. Survivors
were significantly younger at diagnosis, had significantly low-
er EDSS scores and higher KPS scores prior to PML diagno-
sis, and had significantly lower cerebrospinal fluid JC viral
load at the time of diagnosis. Patients with less extensive dis-
ease on MRI at diagnosis had a higher survival rate than those
with widespread disease. Survivors generally had less func-
tional disability pre-PML, at PML diagnosis, and in subse-
quent months. In survivors, functional disability appeared to
stabilize approximately 6 months post-PML diagnosis. In this
analysis, younger age at diagnosis, less functional disability
prior to PML diagnosis, lower JC viral load at diagnosis, and
more localized brain involvement by MRI at the time of diag-
nosis appeared to predict improved survival in natalizumab-
associated PML.
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Introduction
Multiple sclerosis (MS) is an immune-mediated disease
resulting in progressive neurological disability. Natalizumab
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reduces the rate of clinical relapse and improves disability
status in patients with relapsing forms of the disease (Polman
et al. 2006; Belachew et al. 2011). Natalizumab is also asso-
ciated with progressive multifocal leukoencephalopathy
(PML), an opportunistic demyelinating disease of the brain
caused by the JC virus (JCV) (Langer-Gould et al. 2005). In
patients who test positive for anti-JCV antibodies, the risk of
natalizumab-associated PML increases with treatment dura-
tion (especially >2 years of therapy) and prior use of immu-
nosuppressant therapy (Bloomgren et al. 2012).
Although highly variable, survival in patients with ac-
quired immune deficiency syndrome (AIDS)-associated
PML has been linked to specific patient characteristics, JC
viral load in cerebrospinal fluid (CSF) (Yiannoutsos et al.
1999), and underlying immunologic function, such as low
CD4+ cell count at disease onset (Gasnault et al. 2011).
Few data exist regarding prognostic markers of
natalizumab-associated PML. An analysis of the first 35
PML patients concluded that survivors were younger, had a
lower Kurtzke Expanded Disability Status Scale (EDSS)
(Kurtzke 1983) score prior to PML, had a shorter duration of
symptom onset to PML diagnosis, and typically had magnetic
resonance imaging (MRI) findings consistent with more local-
ized disease than patients who did not survive (Vermersch
et al. 2011). However, only 12 PML survivors had
physician-reported disability scores (based on the Karnofsky
Performance Scale [KPS] [Karnofsky and Burchenal 1949])
available beyond 6 months following PML diagnosis. The
small sample size and lack of available follow-up data limited
longitudinal extrapolation of these results.
Patients and methods
As of August 22, 2013, there were 398 confirmed cases of
natalizumab-associated PML globally, all spontaneously re-
ported in the postmarketing setting.
In this study, the diagnosis of PML was confirmed by one
of two sets of criteria:
1. Brain tissue (from biopsy or postmortem examination)
showing evidence of viral cytopathic changes on hema-
toxylin and eosin staining associated with either positive
immunohistochemistry for SV40 or in situ hybridization
for JCV DNA.
2. PCR detection of JCV DNA in CSF or in brain biopsy
specimens, preferably by ultrasensitive quantitative PCR
testing (limit of quantification of ≤50 copies/mL), along
with a detailed description of brain MRI findings consis-
tent with PML (Dong-Si et al. 2012).
Treating physicians were queried at the time of Biogen Idec
case confirmation and every 6 months for up to 24 months
using a PML Data Collection Tool (DCT) (Supplementary
Fig. 1) designed to solicit information regarding a patient’s
PML disease status, survival status, clinical characteristics
(e.g., functional disability using the EDSS [Kurtzke 1983;
Supplementary Table 1a] and KPS [Karnofsky and Burchenal
1949; Supplementary Table 1b]), and additional pertinent data
(e.g., demographics, natalizumab exposure, and prior immu-
nosuppressant use). Because this was an analysis of aggregate
anonymous data collected from reports of serious adverse
events, neither ethics committee approval nor informed con-
sent was required. Patient data were supplemented by infor-
mation captured in the Biogen Idec natalizumab global safety
database. PML patients were categorized by survival status as
of the data cutoff date (August 22, 2013). Survivors were
defined as patients who were alive at the data cutoff date
and had follow-up data for at least 6 months after PML diag-
nosis; nonsurvivors were defined as patients who died at any
time after PML diagnosis. JC viral load (copies/mL) at time of
PML diagnosis was defined as the patient’s earliest positive
quantitative value in a CSF sample (an average value was
calculated if multiple results originated on the same date).
Qualitative JC viral load results without quantification were
excluded. EDSS and KPS data for survivors were analyzed at
the following six time points: on natalizumab pre-PML diag-
nosis (the earliest available score); at PML diagnosis; and four
intervals post-PML diagnosis (6–9, 10–13, 14–17, and
≥18 months). Average scores were calculated if multiple
scores were available within given time intervals. Treating
physicians provided MRI data from the time of PML diagno-
sis. Information regarding date and cause of death was collect-
ed whenever possible.
Statistical analyses
Demographics and predictors of survival
We evaluated differences in demographic and clinical charac-
teristics in survivors and nonsurvivors, overall and stratified
by geography. Survival rates were stratified by PML case
numbers, which were assigned chronologically (1–100, 101–
200, and 201–300).
Categorical variables were presented as frequencies and
compared using chi-square tests. Continuous variables were
assessed for normality using the Shapiro-Wilk test. Age was
the only variable that met the normality assumption, and it was
compared using an independent t test. The Mann-Whitney-
Wilcoxon two-sample test was used to test for differences in
continuous variables that did not meet the normality assump-
tion. All tests assumed a two-sided alternative hypothesis and
a 0.05 significance level uncorrected for multiple compari-
sons. All analyses were conducted using SAS/STAT® soft-
ware, version 9.3, and R (R Development Core Team 2014).
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EDSS and KPS analysis
A weighted polynomial regression model, employing the lo-
cally weighted scatterplot smoothing (LOWESS) algorithm
(Cleveland 1981), was used to assess EDSS and KPS data
and to derive functional outcome by survival status.
The LOWESS curve is a nonparametric regression
method that combines multiple regression models in a
k-nearest-neighbor-based meta-model. Its use is recom-
mended in cases where there is no a priori model to
which scatter data can be fit and works by creating a fit func-
tion based on localized subsets of the data. A curve fitting the
localized models is smoothed by a locally weighted, linear,
least squares method. Here, we use the implementation of
LOWESS provided in the core R language package, “stats”
(R Development Core Team 2014).
Time from PML diagnosis to death
A Kaplan-Meier estimator of the survival function was gener-
ated to model patient vital status. The Kaplan-Meier estimator
is often used in medical research to measure the fraction of
patients living for a certain amount of time after treatment
(Kaplan and Meier 1958). Here, the survival function is based
on the fraction of patients living for a certain amount of time
after PML diagnosis. We used the Kaplan-Meier estimator
implementation provided in the R-language package, “surviv-
al” (Therneau 2013). The model uses type I right-censoring of
data, with survivorship defined in terms of time interval from
date of diagnosis to data cutoff.
Results
Patient demographics and survival
Of the 398 natalizumab-treated patients with PML identified
as of August 22, 2013, 62 patients were alive but had not
reached the 6-month time point after PML diagnosis (early
PML). The remaining 336 patients were alive for at least
6 months after PML diagnosis or had died and therefore were
included in this evaluation. At the time of this analysis, there
were 254 survivors (76 %) and 82 nonsurvivors (24 %). For
the 254 survivors, the mean (median) follow-up time from
PML diagnosis was 16.1 months (17.2 months).
Predictors of survival
Compared with nonsurvivors, survivors were younger, had
better pre-PML EDSS (mean 3.7 and median 3.5 vs mean
and median 5.0; p=0.0028) and KPS scores (mean 81.2 and
median 80 vs mean 70.8 and median 70; p=0.0117), and had
lower JC viral load in the CSF at the time of PML diagnosis
(Table 1). After PML diagnosis, corticosteroid (CS) use was
not different between survivors (78.3 %) and nonsurvivors
(75.6 %).
Comparedwith patients from theUSA, a greater proportion
of patients from Europe (EU) or the rest of the world (ROW)
were survivors (59 vs 85%; p<0.0001). For the first 100 PML
cases (confirmed between August 2008 and March 2011), the
survival rate was 49 % in the USA and 85 % in the EU/ROW.
This geographical difference became smaller over time: USA
58 % and EU/ROW 85 % for the next 100 cases (confirmed
between March 2011 and January 2012); USA 74 % and EU/
ROW 81 % for the next 100 cases (confirmed between Janu-
ary 2012 and October 2012). US patients were generally older
than EU/ROW patients, regardless of the chronologically
assigned case number (Supplementary Table 2); the mean
(median) age in the USA was 53 years (55 years) in
nonsurvivors and 47 years (47 years) in survivors, while the
mean (median) age in the EU/ROWwas 45 years (46 years) in
nonsurvivors and 42 years (42 years) in survivors. There was
no difference in prior IS use or pre-PML EDSS and KPS
scores stratified by geographies (data not shown).
JC viral load adjusted for age
Age at PML diagnosis was a potential confounder
(r=0.0187; p=0.0035) in the relationship between JC
viral load and outcome (survivor/nonsurvivor). There-
fore, JC viral load was adjusted for age in the regression
using a log transformation of JC viral load, with outcome
and age as the independent variables (Fig. 1). Age
remained a significant predictor of survival (p<0.0001).
JC viral load in relation to MRI at diagnosis
Brain MRI results at PML diagnosis were available for
296 pat ien ts , inc luding 223 survivors and 73
nonsurvivors (Table 2). A higher survival rate was seen
in patients with less extensive disease on MRI at diag-
nosis (i.e., unilobar PML) than in those with widespread
disease (79 vs 66 %; Table 2). Of those patients with
less extensive PML lesions (n=115), the majority
(52 %) had frontal lobe lesions, 29 % had occipital or
parietal lobe lesions, 3 % had temporal lobe lesions,
3 % had lesions in the basal ganglia/thalamus, and the
remaining cases were unreported.
For both unilobar and widespread disease, JC viral load at
PML diagnosis was significantly lower in survivors than in
nonsurvivors (unilobar, median 275 copies/mL vs median
2903 copies/mL, p=0.0157; widespread, median 416
copies/mL vs median 1631 copies/mL, p=0.0014) (Supple-
mentary Table 3).





























Fig. 1 Log JC viral load (copies/mL) for PML patients according to survival status (p<0.0001). p value adjusted for age.White horizontal line, median;
horizontal bars, range
Table 1 Patient demographics and baseline characteristics
Characteristic All (N=336) Survivors (n=254) Nonsurvivors (n=82) p value
Age at diagnosis, years (n=332) (n=252) (n=80)
Mean (SD) 45.0 (9.6) 43.5 (9.2) 49.5 (9.7) <0.0001
Median (range) 45 (15–73) 44 (15–71) 50 (24–73)
Gender, female, n (%) 237 (71) 182 (72) 55 (67) 0.4322
Geography, n (%)
USA 119 (35) 70 (59) 49 (41) <0.0001b
EU/ROW 217 (65) 184 (85) 33 (15)
Duration of MS, years (n=116) (n=90) (n=26)
Mean (SD) 14.1 (8.2) 13.3 (7.7) 16.7 (9.1) 0.0909
Median (range) 12 (1–51) 12 (1–51) 15 (6–38)
Natalizumab exposure, months
Mean (SD) 38.6 (14.0) 39.2 (14.0) 36.7 (13.8) 0.1045
Median (range) 38 (8–74) 40 (8–74) 34 (14–72)
JC viral load, copies/mL (n=285) (n=216) (n=69)
Mean (SD) 185,797 (893,482) 91,587 (469,668) 480,715 (1,587,521) <0.0001
Median (range) 500 (1–10,243,280) 386 (1–4,831,575) 2076 (10–10,243,280)
Time from symptom onset to diagnosis, days (n=328) (n=246) (n=82)
Mean (SD) 44.2 (51.9) 41.3 (44.5) 52.9 (69.2) 0.2623
Median (range) 27 (0–368) 26 (0–216) 29 (0–368)
EDSS score, pre-PML (n=123) (n=101) (n=22)
Mean (SD) 3.9 (1.8) 3.7 (1.8) 5.0 (1.7) 0.0028
Median (range) 3.75 (0–8) 3.5 (0–7) 5.0 (2–8)
KPS score, pre-PML (n=84) (n=72) (n=12)
Mean (SD) 79.7 (13.2) 81.2 (12.4) 70.8 (15.1) 0.0117
Median (range) 80 (40–100) 80 (40–100) 70 (40–100)
Prior immunosuppressant usea, n (%) 91 (27) 68 (27) 23 (28)
aMitoxantrone, methotrexate, azathioprine, cyclophosphamide, or mycophenolate
b p value is for comparison of survival rate between USA and EU/ROW. All other p values are for comparison between survivors and nonsurvivors
SD standard deviation
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Functional outcomes of survivors
EDSS scores
At least one EDSS score was available for 194 PML survivors
and 77 nonsurvivors (Fig. 2a). Mean EDSS scores showed
little variation in the months prior to PML diagnosis, when
patients were receiving natalizumab. In general, PML
patients who survived had lower mean pre-PML EDSS
scores than nonsurvivors; this trend was maintained at
PML diagnosis and following diagnosis. Mean EDSS
scores for both patient groups increased shortly after
diagnosis, with a more marked increase in functional
disability observed in nonsurvivors (Fig. 2a). Thereafter,
mean EDSS scores appeared to plateau, and in survivors,
scores appeared to stabilize at approximately 6 months post-
PML diagnosis.
KPS scores
At least one KPS score was available for 191 PML survivors
and 77 nonsurvivors (Fig. 2b). In the months prior to PML
diagnosis, when patients were receiving natalizumab, mean
KPS scores showed little variation for both survivors and
nonsurvivors. The decrease in KPS scores observed shortly
after PML diagnosis, which indicated an increase in functional
disability, was more pronounced in nonsurvivors. Mean KPS
scores, particularly for the surviving patients, appeared to re-
main stable at all subsequent time points.
Correlation between EDSS and KPS scores
To assess the correlation between measures of functional dis-
ability, a weighted polynomial regression model was applied,
as displayed in Supplementary Fig. 2. The EDSS and KPS
were negatively correlated (R2=0.713) in survivors.
Time from PML diagnosis to death and cause of death
Date of death was unknown for three patients with fatal out-
come. For the remaining 79 patients with fatal outcome, the
mean time from date of PML diagnosis to death was
4.7 months. Fifty-nine patients (74.7 %) died within 6 months
of PML diagnosis. Overall survival of the PML population
plateaued around 4–6 months (Fig. 3).











Unilobar, n (%)a 115 (39) 91 (41) 24 (33) 79
Widespread, n (%)b 108 (36) 71 (32) 37 (51) 66
aUnilobar lesions were confined to one lobe
bWidespread lesions involved two or more noncontiguous lobes and/or
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Fig. 2 Functional outcomes as
measured by a EDSS and b KPS
scores for PML patients
according to survival status. Each
symbol represents a single patient
measurement at a single time
point. The light gray lines
represent polynomial regression
trend lines (LOWESS curves) for
survivors; the dark gray lines
represent polynomial regression
trend lines (LOWESS curves) for
nonsurvivors. EDSS and KPS
scores were not available for all
patients at all time points
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Cause of death was unknown for 53 patients; for the re-
maining patients, the cause of death was pneumonia for 11;
cardiorespiratory event for 6; dehydration and nonfeeding for
4; mass effect/edema for 3; and palliative sedation, suicide,
seizure, sepsis, and urosepsis for 1 patient each. Hospice care
was mentioned for 25 patients, 9 of whom died more than
6 months after PML diagnosis.
Discussion
Although PMLwas once considered uniformly fatal, our anal-
ysis of the first 336 confirmed postmarketing cases of
natalizumab-associated PML with up to 24 months of
follow-up data revealed a 76 % survival rate over the study
period. In contrast, survival at 1 year with PML in other dis-
ease populations has been reported to vary from less than 20 to
58 %, depending on the underlying condition (De Luca et al.
1998; Marzocchetti et al. 2009; Hall et al. 1998). Recent ob-
servations suggest an improved 1-year survival rate of 75% in
HIV+ patients who were treated early after disease onset ag-
gressively with effective anti-HIV therapy, resulting in prompt
restoration of CD4+ counts and inhibition of HIV replication
(Gasnault et al. 2011; Fanjul et al. 2013). In contrast to
natalizumab-associated PML, HIV+ PML appears to show a
longer survival with increasing age (Casado et al. 2013), while
age does not seem to influence survival in transplant recipients
with PML (Mateen et al. 2011).
Unlike most other patients with PML, MS patients with
natalizumab-associated PML have a functioning systemic im-
mune system, and therapeutic immune reconstitution may be
rapidly achieved through plasma exchange (Gheuens et al.
2013). Although clinical deterioration in the setting of im-
mune reconstitution inflammatory syndrome (IRIS) occurs
transiently, without any known effective JCV therapy, this
essential therapeutic step is routinely possible in
natalizumab-treated patients. It is notable that there appeared
to be a learning effect in the current study, with survival rates
improving over time in the USA, potentially due to improved
detection and management of PML once diagnosed
(Giacomini et al. 2014).
Our analysis identified several predictors of survival in
natalizumab-associated PML. Younger patients and patients
with less disability prior to PML diagnosis were more likely
to survive, consistent with previous observations (Vermersch
et al. 2011). Although more recent PML cases exhibited fewer
geographical differences in survival, age appeared to be an
important contributor to overall survival when it was stratified
by geography, with US cases being older than ROW cases
(median [range] age 55 years [32−73 years] in the USA and
46 years [30−59 years] in ROW). Older age as a risk factor for
poorer outcomes in PMLmight be important for prescribers to
consider in discussions about PML risk.
The criteria for PML diagnosis used in this study allowed
for the inclusion of PML patients who were diagnosed, with or
without symptoms, on the basis of PCR detection of JCV
DNA in CSF or in brain biopsy specimens and a detailed
description of brain MRI findings consistent with PML. It is
possible that the means of PML diagnosis may have affected
outcomes. In a recently published related analysis, patients
who were asymptomatic when they were diagnosed with
PML had better survival and functional outcomes than pa-
tients who were symptomatic at diagnosis. The average time
to PML diagnosis was shorter in asymptomatic patients than
in symptomatic patients (12 vs 28 days); earlier diagnosis in
asymptomatic patients may have allowed for earlier interven-
tion, which may have led to better outcomes (Dong-Si et al.
2014).
The correlation of disease burden and JC viral load in CSF
is modest, but our findings show that more advanced disease
both by greater MRI lesion burden as well as JC viral load
predicts poorer outcomes. Similarly, in a study of 28 HIV+
and HIV− PML patients, those with a higher JC viral load in
the CSF at the time of PML diagnosis experienced poorer
outcomes (Gasnault et al. 2011). These findingsmay be driven
by fast clearance of the virus in the setting of immune recon-
stitution, which is probably easier to obtain when there is still
localized disease or a lesser amount of antigen. Patients who
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Fig. 3 Kaplan-Meier estimate of
overall survival after PML
diagnosis
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et al. 2011; Delbue et al. 2012). While the association between
JC viral load in the CSF and survival was statistically signif-
icant in our study, this finding should be interpreted with cau-
tion, as the association was weak and the relevance of viral
load in the CSF—which is not the site of clinically meaningful
disease—is unknown.
We did not observe a difference in CS use between survi-
vors and nonsurvivors. CS might enhance survival by
blocking overly aggressive IRIS or might inhibit immune con-
trol of virus by decreasing the frequency of interferon-gamma-
producing JCV-specific CD8+ T cells (Antoniol et al. 2012).
This specific T cell response is considered important in PML
survival (Gheuens et al. 2011). The proportion of patients with
prior use of immunosuppressants did not appear to differ be-
tween survivors and nonsurvivors in this study. While prior
immunosuppressant use is a known risk factor for develop-
ment of natalizumab-associated PML, it is not known to be
related to PML survival.
Most deaths in our study occurred within the first 6 months
after PML diagnosis, consistent with the subacute nature of
PML. As survival appears to stabilize at 15 months, it is un-
likely that the later deaths occurred as a direct consequence of
PML, which is consistent with previous observations
(Marzocchetti et al. 2009; Lima et al. 2010). Higher mortality
in the early era of natalizumab-associated PML may have
resulted from assessment of the prognosis as hopeless and
abandonment of supportive care. Experience suggests that
supportive care and treatment of IRIS allow survival and in
some cases significant functional recovery.
Functional disability stabilized at 6 months post-PML
diagnosis and remained relatively stable even beyond 18
months post-PML diagnosis. Varying levels of disability
(mild to severe) were present at all studied time points.
While not all patients returned to their pre-PML level of
disability, the majority of patients appeared to sustain
moderate to moderate-severe disability throughout the
course of PML and recovery.
Although the EDSS score is designed for MS (Kurtzke
1983) and is commonly used as a functional disability mea-
sure, it can be complicated to calculate and has been criticized
for relying heavily on walking as the main measure of disabil-
ity (Amato and Portaccio 2007). The KPS is not specific for
MS or PML. It can be used across many diseases, and scores
are easier to assess, using an 11-point scale (Karnofsky and
Burchenal 1949). EDSS and KPS are highly correlated (Sup-
plementary Fig. 2), and study results show a higher risk of
mortality in PML if disability is severe prior to treatment.
Clinicians may find this helpful in discussions with patients
with advanced MS who are considering the use of
natalizumab.
Our study has several limitations. Most importantly, da-
ta sets gathered spontaneously in the postmarketing setting
are seldom complete, and this might have introduced an
unknown bias. Another potential source of bias is the
exclusion of PML patients who were alive at the time of
this analysis but had not survived for at least 6 months
from PML diagnosis. Although immune reconstitution is
important, we were not able to reliably evaluate the im-
pact of IRIS or differences in how IRIS may have been
managed across this population. In addition, we were not
able to take into account lesion volume or specific lesion
location. Although there are conflicting results regarding
lesion location and prognosis (Post et al. 1999), lesions
might be worse in certain locations, for instance, the cer-
ebellum, than in others (Lima et al. 2010).
This is the largest study providing longitudinal follow-up
of survival and functional outcomes of natalizumab-
associated PML. Age, JCV viral load in CSF, and extent of
disease on imaging are predictors of survival. Patients quickly
stabilize after the initial phase of disease, and there is a high
correlation between EDSS and KPS scores, the latter being
more easily obtainable. These predicting factors could be use-
ful when considering treatment options for patients and when
counseling them regarding the benefits and risks of treatment
(Rudick 2011).
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